JPRN-UMIN000030095招募中未知
Consolidation treatment of Lenalidomide for patients with adult T-cell leukemia/lymphoma ineligible for hematopoietic stem cell transplant. - Consolidation Lenalidomide for Transplant Ineligible ATL Patients
orth Japan Hematology Study Group0 个研究点目标入组 15 人开始时间: 2017年11月27日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 100years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Positivity for HBs antigen 2. Positivity for HIV antibody 3. Double cancers 4. Administration of lenalidomide so far 5. Using Dialysis 6. Heat failure or ischemic heart disease 7. Acute hepatitis or Liver cirrhosis 8. Active infection 9. Active thrombotic diseases 10. Allergy for thalidomide 11. Pregnant or breast-feeding woman 12. Difficult of adherence for drug administration 13. Severe mental disorder 14.An inappropriate patient judged by the medical attendant
研究者
相似试验
已完成
不适用
Phase II study of lenalidomide consolidation/maintenance therapy after autologous stem cell transplantation in patients with symptomatic multiple myeloma.Multiple myelomaJPRN-UMIN000004421Japan Study Group for Cell Therapy and Transplantation37
撤回
2 期
enalidomide with epigenetic therapy in relapsed or refractory Acute Myeloid Leukaemia (AML)-Phase IIrelapsed and refractory acute myeloid leukaemiaCancer - Leukaemia - Acute leukaemiaACTRN12612000312842Australasian Leukaemia and Lymphoma Group120
已完成
1 期
enalidomide with epigenetic therapy in relapsed or refractory Acute Myeloid Leukaemia (AML)-Phase IRelapsed or refractory Acute Myeloid Leukaemia (AML)Cancer - Leukaemia - Acute leukaemiaBlood - Haematological diseasesACTRN12612000303842Australasian Leukaemia and Lymphoma Group20
进行中（未招募）
不适用
SALVAGE TREATMENT WITH LENALIDOMIDE AND DEXAMETHASONE (LEN-DEX) IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL) - NDTreatment of patients with MCL relapsed or refractory to at least one line of chemotherapy, not eligible for or relapsed after more intensive treatments.MedDRA version: 9.1Level: LLTClassification code 10061275Term: Mantle cell lymphomaEUCTR2008-000044-14-ITIIL INTERGRUPPO ITALIANO LINFOMI ONLUS
进行中（未招募）
不适用
A Phase 1/2 Study of Lenalidomide in combination with Bendamustine (LEBEN) in relapsed and primary refractory Hodgkin Lymphomarelapsed and primary refractory Hodgkin LymphomaMedDRA version: 14.1Level: LLTClassification code 10020328Term: Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002810-35-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE